Theranostics · 2019 · 71 citations · 40 references
MedicineCancer BiologyOncologyChemotherapyMolecular OncologyOncogenesCancer Cell SignalingChemotherapy ResistanceMetastatic Signaling PathwaysOncogenic Signaling PathwaysSignal Transduction In CancerAnticancer Drug ResistanceEpithelial-mesenchymal Transition MarkersHepatocellular Carcinoma MetastasisHepatocellular Carcinoma PathogenesisP53 InactivationProtein Binding In OncologyTherapeutic Resistance MechanismsWnt In Cancer
The devastating prognosis of hepatocellular carcinoma (HCC) is partially attributed to chemotherapy resistance. Accumulating evidence suggests that the epithelial-mesenchymal transition (EMT) is a key driving force of carcinoma metastasis and chemoresistance in solid tumors. Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5), as an EMT inducer, is involved in the potentiation of Wnt signaling in HCC. This study proposes uncovering the roles of Lgr5 in Doxorubicin (Dox) resistance of HCC to improve treatment efficacy for HCC. Methods: We investigated the expression and significance of Lgr5 in HCC tissue and different cell lines. The effect of Lgr5 in EMT and Dox resistance was analyzed in HCC cells and implanted HCC tumor models. A two-hybrid analysis, using the Lgr5 gene as the bait and a HCC cDNA library, was used to screen targeted proteins that interact with Lgr5. The positive clones were identified by coimmunoprecipitation (Co-IP) and Glutathione-S-transferase (GST) pull-down. The impact of the interaction on Dox resistance was investigated by a series of assays in vitro and in vivo . Result: We found that Lgr5 was upregulated and positively correlated with poor prognosis in HCC. Additionally, it functioned as a tumor promoter to increase cell migration and induce EMT in HCC cells and increase the resistance to Dox. We identified programmed cell death protein 5 (PDCD5) as a target gene of Lgr5 and we found that PDCD5 was responsible for Lgr5-mediated Dox resistance. Further analysis with Co-IP and GST pull-down assays showed that the N-terminal extracellular domain of Lgr5 could directly bind to PDCD5. Lgr5 induced p53 degradation by blocking the nuclear translocation of PDCD5 and leading to the loss of p53 stabilization. Lgr5 showed a protection against the inhibition of Dox on the growth of tumor subcutaneously injected. Moreover, Lgr5 suppressed Dox-induced apoptosis via the p53 pathway and attenuated the cytotoxicity of Dox to HCC. Conclusion: Lgr5 induces the EMT and inhibits apoptosis, thus promoting chemoresistance by regulating the PDCD5/p53 signaling axis. Furthermore, Lgr5 may be a potential target gene for overcoming Dox resistance.
40
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Identification of stem cells in small intestine and colon by marker gene Lgr5
Nick Barker, Johan H. van Es, Jeroen Kuipers et al. · Nature · 2007 · 5.7K citations
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
Meritxell Huch, Craig Dorrell, Sylvia F. Boj et al. · Nature · 2013 · 1.6K citations
Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling
Wim de Lau, Nick Barker, Teck Yew Low et al. · Nature · 2011 · 1.3K citations